open access

Vol 10, No 6 (2009): Practical Diabetology
Review articles (submitted)
Published online: 2010-05-11
Get Citation

Rationale for starting insulin therapy in type 2 diabetes patients with once-daily Levemir®. Background of the SOLVE study in combination therapy

Grzegorz Dzida, Iwona Tarnowska, Gajane Żurawska
Diabetologia Praktyczna 2009;10(6):217-222.

open access

Vol 10, No 6 (2009): Practical Diabetology
Review articles (submitted)
Published online: 2010-05-11

Abstract

The primary goal of the management of diabetes mellitus is the attainment of normoglycaemia, or near normoglycaemia. The importance of such achievements in reducing or delaying the occurrence of the micro and macro vascular complications of diabetes was clearly illustrated in the Diabetes Control and Complications Study (DCCT) and in the United Kingdom Prospective Diabetes Study (UKPDS). Treatment of Type 2 diabetes has during recent years moved from secondary (or specialist physician) to primary (or general practitioner/family physician) care thus increasing the number of physicians and patients initiating insulin therapy in combination with oral antidiabetics drugs (OADs). With such diversified use, there is a need to complement the data from randomized controlled trials supporting such recommendation with data from large observational studies in real-life setting. Such studies sub serve the primary objective of monitoring safety of such newly-approved use in real-life setting in a large population. SOLVE study aims to document the safety of Levemir® when used once-daily in combination with OADs in type 2 diabetes in a real-life setting. In current review we also discuss need of early initiating insulin therapy in patients with type 2 diabetes and why once daily insulin detemir is a good choice for that.

Abstract

The primary goal of the management of diabetes mellitus is the attainment of normoglycaemia, or near normoglycaemia. The importance of such achievements in reducing or delaying the occurrence of the micro and macro vascular complications of diabetes was clearly illustrated in the Diabetes Control and Complications Study (DCCT) and in the United Kingdom Prospective Diabetes Study (UKPDS). Treatment of Type 2 diabetes has during recent years moved from secondary (or specialist physician) to primary (or general practitioner/family physician) care thus increasing the number of physicians and patients initiating insulin therapy in combination with oral antidiabetics drugs (OADs). With such diversified use, there is a need to complement the data from randomized controlled trials supporting such recommendation with data from large observational studies in real-life setting. Such studies sub serve the primary objective of monitoring safety of such newly-approved use in real-life setting in a large population. SOLVE study aims to document the safety of Levemir® when used once-daily in combination with OADs in type 2 diabetes in a real-life setting. In current review we also discuss need of early initiating insulin therapy in patients with type 2 diabetes and why once daily insulin detemir is a good choice for that.
Get Citation

Keywords

diabetes mellitus type 2; basal insulins; insulin detemir; SOLVE

About this article
Title

Rationale for starting insulin therapy in type 2 diabetes patients with once-daily Levemir®. Background of the SOLVE study in combination therapy

Journal

Clinical Diabetology

Issue

Vol 10, No 6 (2009): Practical Diabetology

Pages

217-222

Published online

2010-05-11

Bibliographic record

Diabetologia Praktyczna 2009;10(6):217-222.

Keywords

diabetes mellitus type 2
basal insulins
insulin detemir
SOLVE

Authors

Grzegorz Dzida
Iwona Tarnowska
Gajane Żurawska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl